BioCentury | Dec 18, 2020
Product Development

Realities of limited manufacturing capacity for COVID-19 vaccines hit Horizon’s Tepezza launch

...order the prioritization of the COVID-19 vaccine manufacturing.TARGETSIGF1R (CD221) – Insulin-like growth factor-1 (IGF-1) receptor Stephen Hansen Tepezza, teprotumumab (hzn-001, rv001, r1507, rg1507) Horizon...
BioCentury | Oct 3, 2020
Product Development

Oral drugs and treatments for life-threatening diseases stand out among new product launches

...siponimod (BAF312) Evenity, romosozumab (AMG 785, CDP7851, anti-sclerostin antibody) Reblozyl, luspatercept-aamt (ACE-536) Nurtec ODT, rimegepant (BHV-3000, bms-927711) Ubrelvy, ubrogepant (MK-1602) Tepezza, teprotumumab (hzn-001, rv001, r1507, rg1507) BeiGene...
BioCentury | Jul 10, 2020

2Q20 Wrap: Biotech bounce

...STARS trial missed its primary and secondary endpoints. Meredith Durkin Wolfe, Associate Editor, Data & Analytics INO-4800 NVX-CoV2373 sarizotan (EMD-128130) NC318 NC410 Tepezza, teprotumumab (HZN-001, RV001, r1507, rg1507) Moderna...
Items per page:
1 - 3 of 3